ONCOETHIX
Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and... handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.
ONCOETHIX
Industry:
Biotechnology Health Care Medical
Founded:
2007-01-01
Address:
Lausanne, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.oncoethix.com
Total Employee:
51+
Status:
Active
Contact:
41 21 616 03 60
Email Addresses:
[email protected]
Total Funding:
22.2 M CHF
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
MetaboStem
MetaboStem is a Biotechnology company developing breakthrough oncology drugs
Neumora Therapeutics
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Current Advisors List
Current Employees Featured
Founder
Investors List
Andera Partners
Andera Partners investment in Series B - OncoEthix
SV Health Investors
SV Health Investors investment in Series B - OncoEthix
Endeavour Vision
Endeavour Vision investment in Series B - OncoEthix
Edmond de Rothschild Private Equity
Edmond de Rothschild Private Equity investment in Series B - OncoEthix
Index Ventures
Index Ventures investment in Series B - OncoEthix
Endeavour Vision
Endeavour Vision investment in Series A - OncoEthix
Index Ventures
Index Ventures investment in Series A - OncoEthix
More informations about "OncoEthix"
OncoEthix - Crunchbase Company Profile & Funding
Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, โฆSee details»
Organization | OncoEthix
Organization Overview. First Clinical Trial. 2012 NCT01724320. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Oncoethix GmbH Active Ingredients. Drugs in โฆSee details»
Merck Acquires OncoEthix, a Privately Held Oncology Company โฆ
Dec 18, 2014 $110 million to OncoEthix. Additional milestone payments of up to $265 million are contingent upon certain clinical and regulatory events being achieved. About OncoEthix. โฆSee details»
OncoEthix Company Profile 2024: Valuation, Investors โฆ
OncoEthix General Information Description. Developer of oncology drug candidates. The company's lead product, OTX015, is an orally administered synthetic small molecule targeted to BET bromodomain proteins 2/3/4.See details»
OncoEthix - Contacts, Employees, Board Members, Advisors
Oncoethix is a clinical-stage biotechnology company developing cancer drugs.See details»
Merck acquires oncology drug development company โฆ
Dec 18, 2014 About OncoEthix Founded in 2009, OncoEthix is a Swiss-based privately held biotechnology company aiming to develop a small portfolio of oncology drug candidates. The Companyโs lead product, OTX015, is an โฆSee details»
Merck : Acquires OncoEthix, a Privately Held Oncology Company ...
Dec 18, 2014 About OncoEthix. Founded in 2009, OncoEthix is a Swiss-based privately held biotechnology company aiming to develop a small portfolio of oncology drug candidates. The โฆSee details»
Oncoethix GmbH - Drug pipelines, Patents, Clinical trials - Synapse
Explore Oncoethix GmbH with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, and 1 literature, Drug:Birabresib dihydrate, Azacitidine, PTX-008.See details»
OncoEthix - Funding, Financials, Valuation & Investors - Crunchbase
Oncoethix is a clinical-stage biotechnology company developing cancer drugs. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. ...See details»
Merck acquires OncoEthix, a privately held oncology company โฆ
Dec 19, 2014 Financial terms of the acquisition include an upfront payment of up to $110 million to OncoEthix. Additional milestone payments of up to $265 million are contingent upon certain โฆSee details»
OncoEthix - EquityNet
Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & โฆSee details»
Oncoethix - Lausanne, Switzerland - bionity.com
Founded in 2009, Oncoethix is a Swiss-based privately held biotechnology Company that is developing a small portfolio of oncology drug candidates. The Companyโs lead product, โฆSee details»
Merck acquires Swiss oncology drug development company โฆ
Dec 21, 2014 OncoEthix will receive an upfront payment of up to $110m from Merck. Upon certain clinical and regulatory events being achieved, OncoEthix will also receive additional โฆSee details»
Merck Up on OncoEthix Acquisition Deal, Oncology in Focus
Dec 19, 2014 Merck (MRK) acquired Swiss biotech privately held company, OncoEthix, and added a promising experimental early-stage candidate, OTX015, to its oncology portfolio.See details»
Esteban Cvitkovic - Co-Founder @ OncoEthix - Crunchbase
Primary Organization . OncoEthix . Location Paris, Ile-de-France, France; Regions European Union (EU), Europe, Middle East, and Africa (EMEA) ... Highlights of his career in industry โฆSee details»
UPDATED: Merck beefs up its cancer drug pipeline in $375M โฆ
Dec 18, 2014 Further beefing up its rapidly growing pipeline for new cancer drugs, Merck has stepped in to buy out Switzerland's OncoEthix in a deal worth upward of $375 million. And the โฆSee details»
Merck stumps up $375m for cancer firm OncoEthix - PMLiVE
Dec 19, 2014 Follows $8.4bn deal to buy CubistSee details»
Yves Paternot - Founder & Chairman @ OncoEthix - Crunchbase
Primary Organization . OncoEthix . Gender Male; Mr. Paternot has been a private equity investor, either directly or through investment funds in the USA, UK, France, and Switzerland, since โฆSee details»
BET-bromodomain (BRD) inhibitor OTX015: Final results of the โฆ
Background: OTX015 (Oncoethix) is a small molecule that specifically binds to BRDs 2, 3 and 4, thereby inhibiting binding to acetylated histones, resulting in downregulation of several โฆSee details»
Patrice Herait - Chief Medical Officer & Founder @ OncoEthix ...
Primary Organization . OncoEthix . Gender Male; Dr. Herait is a medical oncologist, also trained in clinical hematology, who serves as an independent medical consultant to companies โฆSee details»